Free Trial
NYSE:PRGO

Perrigo Q4 2024 Earnings Report

Perrigo logo
$26.69 +0.02 (+0.07%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$26.64 -0.05 (-0.17%)
As of 08/1/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo EPS Results

Actual EPS
$0.93
Consensus EPS
$0.92
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Perrigo Revenue Results

Actual Revenue
$1.14 billion
Expected Revenue
$1.20 billion
Beat/Miss
Missed by -$57.66 million
YoY Revenue Growth
N/A

Perrigo Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Thursday, February 27, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Perrigo's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Perrigo Earnings Headlines

Perrigo Announces Quarterly Dividend
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
Perrigo (NYSE:PRGO) Cut to "Hold" at Wall Street Zen
See More Perrigo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Perrigo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Perrigo and other key companies, straight to your email.

About Perrigo

Perrigo (NYSE:PRGO) provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

View Perrigo Profile

More Earnings Resources from MarketBeat